A logo of Blackstone is pictured in Manhattan, New York City, U.S. July 29, 2025. REUTERS/Mike Segar Purchase Licensing Rights, opens new tab
CompaniesJuly 9 (Reuters) - Private equity groups Blackstone (BX.N), opens new tab and TPG (TPG.O), opens new tab are seeking more than $4 billion for medical technology firm Hologic's surgical unit, the Financial Times reported on Thursday, citing people familiar with the matter.
Here are more details:
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The two firms are working with advisers on a sale of the division, which makes surgical equipment used by gynecologists, FT reported.
Blackstone and TPG announced the acquisition of Hologic last year for $18.3 billion using cash and debt, one of the largest buyouts of a medical device company. The deal closed in April 2026.
Reuters could not verify the report. TPG, Blackstone and Hologic did not immediately respond to Reuters' requests for comment outside business hours.
The FT said the private equity groups are now looking to pay down debt and repay investors from their Hologic buyout.
The potential sale comes as strains in private credit spill into adjacent private equity markets, prompting firms to find ways to return cash to investors.
Blackstone is among the private credit funds that have recently faced redemption pressures. The company capped withdrawals at its flagship private credit fund last month after receiving increased redemption requests.
Reporting by Chandni Shah in Bengaluru; Editing by Sonia Cheema and Eileen Soreng
Our Standards: The Thomson Reuters Trust Principles., opens new tab
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women's health, today released its 2025 Sustainability Report. The new report coincides with Hologic's 40th anniversary and underscores how the company's longstanding purpose — to enable healthier lives for women everywhere, every day — continues to drive progress for patients, communities and the planet. “We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help.
Court orders Siemens to halt production and recall and destroy products across Germany, France and the Netherlands
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries.
On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1
In addition to the broad injunction against Siemens, recall and destruction of infringing systems, Hologic will receive retroactive and future damages and costs to be determined by the Court. Siemens must also refund customers of the infringing systems for the purchase price paid and reimburse them for logistics and related costs as part of the recall.
“This ruling is a decisive validation of the strength and originality of Hologic’s innovation —and, more importantly, of the standards we believe women deserve in breast cancer screening,” said Essex Mitchell, Chief Operating Officer at Hologic. “Our technologies are designed to help detect cancer earlier, improve diagnostic confidence and ultimately save lives. When other companies infringe on our patented inventions, it risks undermining the development of new and innovative products that give physicians the ability to deliver the care patients depend on. Hologic will continue to work to ensure clinicians have access to the most advanced, proven technologies and that women worldwide have access to the latest screening innovations.”
Read more about the decision on the UPC’s website here.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com.
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to [email protected].
Hologic, The Science of Sure and Envision are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
References:
* Siemens Healthineers AG, Siemens Healthcare GmbH, Siemens Healthineers Nederland B.V. and Siemens Healthcare SAS (Together: “Siemens”).
Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new stake in Hologic, Inc. (NASDAQ: HOLX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 8,539 shares of the medical equipment provider's stock, valued at approximately $576,000. A number of other
Cinctive Capital Management LP increased its stake in Hologic, Inc. (NASDAQ: HOLX) by 53.4% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,404 shares of the medical equipment provider's stock after acquiring an additional 23,119 shares during the period. Cinctive Capital Management LP's holdings
Key Takeaways Hologic's data reveals rising rates of women screened for blood pressure, cancer and diabetes.Hologic finds STI testing stagnant at 10%, with no improvement in five years.Hologic expands molecular diagnostics with Aptima tests for STIs and HPV. Hologic’s fifth edition of the Global Women’s Health Index highlights a persistent screening gap for key preventable conditions. Developed in partnership with Gallup, the Index tracks progress in women’s health and well-being worldwide, based on an annual survey of 145,000 people in 144 countries and territories.
In year five, 39% of women were tested for high blood pressure, 13% for cancer and 24% for diabetes — all up several points from the previous year and also at their five-year highs. However, sexually transmitted infection (STI) testing was the only area that showed no improvement, with just 10% of women reporting being tested for an STI in the past 12 months, unchanged since year one. This leaves nearly 2 billion women of reproductive age at risk of infertility, increased maternal and fetal mortality, and serious diseases.
Hologic’s Aptima family of molecular diagnostic assays covers common STIs such as chlamydia and gonorrhea, certain high-risk human papillomavirus (HPV) strains, Mycoplasma genitalium and Herpes Simplex viruses 1 and 2. The FDA-cleared BV and CV/TV assays for diagnosing vaginitis — a prevalent health issue affecting millions of women annually — now rank as the company’s second-largest assay worldwide. These tests have been a major growth driver for the past several quarters. Overall, Molecular Diagnostics business revenues fell 3.5% in the first quarter of fiscal 2026, partly due to lower sales of Aptima CT/NG and HPV assays and related collection devices.
In 2026, an estimated 13,490 new cases of invasive cervical cancer are likely to be diagnosed, with roughly 4,200 deaths — many of which are preventable with regular screening and appropriate follow-up on abnormal results. In February, Hologic expanded its cervical health portfolio with FDA approval for Aptima HPV Assay for clinician-collected HPV primary screening.
HOLX’s Peer UpdatesQIAGEN (QGEN - Free Report) recently received FDA clearance for the use of all QIAstat-Dx Gastrointestinal Panels on the QIAstat-Dx Rise automated syndromic testing system. With this development, laboratories can now run respiratory and gastrointestinal panels, including comprehensive and Mini panels, on one scalable automated system. QIAGEN launched QIAstat-Dx Rise in the United States in September 2025 to address the rising demand for higher testing capacity and increased automation in molecular diagnostics laboratories.
GE HealthCare (GEHC - Free Report) has completed the acquisition of medical imaging software provider Intelerad. The latter’s technology and customer base will extend GE HealthCare’s reach into high-growth specialized clinics and ambulatory care environments, complementing the company’s strength in hospital-based imaging. Intelerad’s revenues in the first full year of ownership are expected to be roughly $270 million, of which approximately 90% is recurring.
The Zacks Rundown for HologicIn the past 12 months, Hologic shares have risen 23.1% against the industry’s 6.7% fall.
Image Source: Zacks Investment Research
In terms of valuation, Hologic is trading at a forward five-year price-to-earnings (P/E) of 16.11X, lower than its median and industry average.
Image Source: Zacks Investment Research
Take a look at how estimates for Hologic’s earnings are shaping up.
Image Source: Zacks Investment Research
HOLX stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this medical device maker have returned +0.3% over the past month versus the Zacks S&P 500 composite's -3.6% change. The Zacks Medical - Instruments industry, to which Hologic belongs, has lost 6.2% over this period. Now the key question is: Where could the stock be headed in the near term?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Hologic is expected to post earnings of $1.09 per share, indicating a change of +5.8% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of $4.49 for the current fiscal year indicates a year-over-year change of +5.4%. This estimate has changed +0.2% over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $4.9 indicates a change of +9% from what Hologic is expected to report a year ago. Over the past month, the estimate has changed +0.5%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Hologic is rated Zacks Rank #4 (Sell).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Hologic, the consensus sales estimate of $1.05 billion for the current quarter points to a year-over-year change of +4%. The $4.26 billion and $4.48 billion estimates for the current and next fiscal years indicate changes of +4% and +5.2%, respectively.
Last Reported Results and Surprise HistoryHologic reported revenues of $1.05 billion in the last reported quarter, representing a year-over-year change of +2.5%. EPS of $1.04 for the same period compares with $1.03 a year ago.
Compared to the Zacks Consensus Estimate of $1.07 billion, the reported revenues represent a surprise of -2.14%. The EPS surprise was -4.59%.
Over the last four quarters, Hologic surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Hologic is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Hologic. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
Key Takeaways Hologic's buyout of up to $79 per share offers just 0.6% upside from recent levels.Align Technology hit $4B revenues in 2025, with aligner volumes rising 6.7% globally.DSO growth and digital tools adoption are boosting Align Technology's long-term expansion. Hologic and Align Technology (ALGN - Free Report) are two well-established players in the medical technology (MedTech) market, each with distinct niche. Hologic develops diagnostics, surgical, and medical imaging technologies to advance women’s health. In the last five years, a series of tactical acquisitions helped expand the company’s existing businesses.
Align Technology designs and sells Invisalign clear aligners for the treatment of malocclusions, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (“CAD/CAM”) software for dental laboratories and practitioners. The company also invests in clinical support, product improvements, technological innovations, clinical education and advertising to supplement growth.
With the global MedTech market projected to reach $666.25 billion, per Statista, investors are closely tracking opportunities in this sector to enhance their portfolio. Here’s a closer look at how the two companies currently stack up.
The Case for HOLXHologic’s Diagnostics division is largely driven by sales of the Molecular Diagnostics assays. Performance wise, the unit’s revenues fell 3.5% in the first quarter of 2026, mainly due to lower sales of COVID-19 tests and legacy assays for sexually transmitted infections (STIs). The decline was partially offset by stronger sales of BV CV/TV and Panther Fusion assays.
Last year, Hologic’s new Panther Fusion Gastrointestinal (GI) Bacterial and Expanded Bacterial Assays secured the FDA’s 510(k) clearance and CE-IVDR approval in the European Union. In addition, Biotheranostics is seeing strong adoption of Breast Cancer Index (BCI), a test that determines the benefit of extended endocrine therapy.
Within Breast Health, the acquisition of Endomagnetics in 2024 enhanced the Interventional business with cutting-edge products and R&D capabilities, contributing to the 1.8% revenue growth in the first quarter. Hologic is set to commercially launch the Envision Mammography Platform this year, offering patients a high-speed 3D mammogram with an industry-leading 2.5-second scan time.
The GYN Surgical division held momentum, with first-quarter sales up 8.7% year over year, driven by the Gynesonics acquisition and higher sales volume of MyoSure devices and Fluent Fluid Management products.
Hologic’s $18.3 billion take-private deal is edging toward completion, with 99.8% shareholder approval secured at the Feb. 5 special meeting. Under the terms, Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash, plus a non-tradable contingent value right (CVR) tied to certain global Breast Health revenue goals in fiscal 2026 and 2027. The aggregate purchase price of up to $79 per share represents a 46% premium to the May 23 closing price. With the stock closing yesterday’s session at $75.54, the cash offer implies a mere 0.6% upside.
The Case for ALGNAlign Technology’s total revenues reached a record $4 billion in 2025. In the fourth quarter, clear aligner volumes increased 6.7% year over year, driven by strong performance in EMEA, Latin America and APAC, along with stability in North America, and supported by growth among adult, teen and pediatric patients, as well as across GP and orthodontic channels.
A major strategic growth channel for Align Technology is the Dental service and orthodontic service organizations, DSOs or OSOs, which are growing faster than the traditional practices globally. Their scale, operational discipline, and need for consistent, tech-enabled workflows are driving rapid adoption of the company’s Invisalign system, iTero scanners and fully digital workflows across large networks of general dentists and orthodontists.
Align Technology’s portfolio strategy, including products with lower upfront cost options, is expanding access for doctors while supporting margins. Products such as Invisalign First, the Invisalign palate expander and Mandibular Advancement with Occlusal Blocks (MAOB) continues to fuel year-over-year growth across all regions. As of December 2025, more than 296,000 active Invisalign-trained doctors have treated more than 22 million people worldwide, including over 6.5 million teens.
The company’s expanding suite of digital diagnostic tools, including Align Oral Health Suite and Align X-ray Insights, supports earlier diagnosis and more informed treatment planning. When combined with the restorative capabilities of exocad and the visualization strength of iTero, these tools connect straightening, function and restorative care with a unified digital platform.
As of 2025 end, the company’s cash and cash equivalents totaled $1.09 billion with zero debt on its balance sheet.
EPS Projections for HOLX & ALGNThe Zacks Consensus Estimate for Hologic’s fiscal 2026 earnings indicates 5.4% year-over-year growth to $4.49. In the past 60 days, the estimate has moved downward.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Align Technology’s 2026 EPS indicate 6.7% year-over-year growth to $11.21. The estimate has been revised upward in the past 60 days.
Image Source: Zacks Investment Research
HOLX vs. ALGN: Price Performance & ValuationIn the past three months, Hologic shares have climbed 1.5%, whereas Align Technology surged 13.2%.
Image Source: Zacks Investment Research
Hologic currently trades at a forward, two-year, price-to-sales (P/S) of 3.86X, slightly higher than its median. Align Technology’s 3.02X P/S sits below its median.
Image Source: Zacks Investment Research
End NoteWhile Hologic carries strong underlying fundamentals, lower COVID testing and legacy STI test sales have weighed on its recent Diagnostics performance. With its buyout deal progressing, the small spread between the cash offer price and current levels suggests limited upside. Hence, it seems wise for current shareholders to consider exiting their position.
On the other hand, Align Technology is driving record Clear Aligner volume growth and continues to make strong progress with DSOs, its strategic growth channel. Analyst sentiment remains positive, reflected in the company’s rising earnings estimates. Given its attractive valuation, existing investors may want to retain their stock position for long-term gains.
ALGN carries a Zacks Rank #3 (Hold), while HOLX has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic, Inc. (NASDAQ: HOLX - Get Free Report)'s stock price reached a new 52-week high during trading on Thursday. The stock traded as high as $75.75 and last traded at $75.6350, with a volume of 31208 shares trading hands. The stock had previously closed at $75.52. Wall Street Analysts Forecast Growth Several analysts recently issued
Hologic has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this medical device maker have returned +0.1%, compared to the Zacks S&P 500 composite's -7.6% change. During this period, the Zacks Medical - Instruments industry, which Hologic falls in, has lost 9.9%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current quarter, Hologic is expected to post earnings of $1.09 per share, indicating a change of +5.8% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
The consensus earnings estimate of $4.49 for the current fiscal year indicates a year-over-year change of +5.4%. This estimate has remained unchanged over the last 30 days.
For the next fiscal year, the consensus earnings estimate of $4.9 indicates a change of +9% from what Hologic is expected to report a year ago. Over the past month, the estimate has remained unchanged.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Hologic.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Hologic, the consensus sales estimate of $1.05 billion for the current quarter points to a year-over-year change of +4%. The $4.26 billion and $4.48 billion estimates for the current and next fiscal years indicate changes of +4% and +5.2%, respectively.
Last Reported Results and Surprise HistoryHologic reported revenues of $1.05 billion in the last reported quarter, representing a year-over-year change of +2.5%. EPS of $1.04 for the same period compares with $1.03 a year ago.
Compared to the Zacks Consensus Estimate of $1.07 billion, the reported revenues represent a surprise of -2.14%. The EPS surprise was -4.59%.
Over the last four quarters, Hologic surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.
ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Hologic is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Hologic. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.
Exchange Traded Concepts LLC lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 46.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 13,488 shares of the medical equipment provider’s stock after selling 11,714 shares during the period. Exchange Traded Concepts LLC’s holdings in Hologic were worth $1,005,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the stock. NewEdge Wealth LLC lifted its holdings in shares of Hologic by 3.8% during the third quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock worth $281,000 after purchasing an additional 138 shares during the period. Savant Capital LLC increased its holdings in Hologic by 0.9% in the 3rd quarter. Savant Capital LLC now owns 19,776 shares of the medical equipment provider’s stock worth $1,335,000 after buying an additional 170 shares during the period. UMB Bank n.a. increased its holdings in Hologic by 38.7% in the 3rd quarter. UMB Bank n.a. now owns 620 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 173 shares during the period. Farther Finance Advisors LLC raised its position in Hologic by 6.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,712 shares of the medical equipment provider’s stock worth $183,000 after buying an additional 174 shares during the last quarter. Finally, OneDigital Investment Advisors LLC raised its position in Hologic by 3.2% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 6,105 shares of the medical equipment provider’s stock worth $412,000 after buying an additional 191 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.
Hologic Stock Performance Shares of NASDAQ:HOLX opened at $75.65 on Friday. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.78. The business has a 50 day moving average of $75.28 and a two-hundred day moving average of $73.60. The company has a market capitalization of $16.89 billion, a PE ratio of 31.52, a PEG ratio of 2.24 and a beta of 0.70.
Hologic (NASDAQ:HOLX – Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.87 EPS. As a group, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.
Analysts Set New Price Targets HOLX has been the topic of several recent research reports. Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their price objective for the company from $79.00 to $78.00 in a report on Monday, January 5th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $78.42.
Get Our Latest Analysis on Hologic
About Hologic (Free Report)
Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.
Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.
See Also Five stocks we like better than Hologic Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Free Report).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEExchange Traded Concepts LLC Purchases 2,608 Shares of iShares MSCI USA Momentum Factor ETF $MTUM
NEXT HEADLINE »Exchange Traded Concepts LLC Increases Stake in Hecla Mining Company $HL
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Blackstone/TPG Acquisition.
Hologic, Inc. (NASDAQ:HOLX – Get Free Report) saw some unusual options trading on Monday. Investors bought 3,509 put options on the company. This represents an increase of approximately 207% compared to the average daily volume of 1,144 put options.
Institutional Investors Weigh In On Hologic Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its stake in Hologic by 294.3% in the second quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after purchasing an additional 8,227,318 shares during the period. HBK Investments L P purchased a new stake in Hologic in the fourth quarter worth $625,716,000. Geode Capital Management LLC grew its stake in Hologic by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 5,919,013 shares of the medical equipment provider’s stock worth $439,228,000 after purchasing an additional 22,019 shares during the period. Victory Capital Management Inc. grew its stake in Hologic by 2.6% in the fourth quarter. Victory Capital Management Inc. now owns 5,609,912 shares of the medical equipment provider’s stock worth $417,882,000 after purchasing an additional 139,867 shares during the period. Finally, FIL Ltd grew its stake in Hologic by 10,317.8% in the fourth quarter. FIL Ltd now owns 5,227,433 shares of the medical equipment provider’s stock worth $389,391,000 after purchasing an additional 5,177,255 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.
Hologic News Summary Here are the key news stories impacting Hologic this week:
Positive Sentiment: The company confirmed a go‑private acquisition by Blackstone/TPG and announced that CEO Steve MacMillan will retire upon close — this buyout typically implies a takeover premium for public shareholders and explains upward pressure on the share price. Business Wire: Hologic CEO to Retire Upon Close of Go‑Private Transaction MarketWatch: Hologic Chairman, CEO Steve MacMillan to Step Down Positive Sentiment: Multiple outlets report the CEO retirement is tied to the private equity deal (expected close triggers executive transition) — that reduces surprise governance risk at close and clarifies the exit path for public holders. MassDevice: Hologic CEO MacMillan to retire following private equity acquisition TipRanks: CEO Retirement Announced Amid Buyout Neutral Sentiment: Analysts and index watchers are discussing S&P 500 roster changes tied to the acquisition — Hologic’s pending take‑private opens a slot in the index; names like Marvell, Alnylam and Veeva are cited as potential replacements, which matters to index‑tracking flows but is one‑step removed from HOLX’s buyout valuation. MarketWatch: S&P 500 change may be imminent Morningstar: Stock joining the S&P 500 Negative Sentiment: Traders showed unusually large put buying today (roughly a 207% increase vs. average daily put volume), signaling either hedging ahead of deal uncertainty or speculative downside bets — increased puts can add short‑term volatility and reflect some investor caution. (options flow report) Wall Street Analyst Weigh In A number of equities analysts recently commented on HOLX shares. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and decreased their target price for the company from $79.00 to $78.00 in a report on Monday, January 5th. Finally, Argus downgraded Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Two investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $78.42.
Check Out Our Latest Research Report on HOLX
Hologic Price Performance Shares of Hologic stock opened at $76.01 on Tuesday. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The company has a market cap of $16.97 billion, a PE ratio of 31.67, a P/E/G ratio of 2.24 and a beta of 0.70. The business has a 50 day moving average of $75.29 and a 200 day moving average of $73.77. Hologic has a 52 week low of $51.90 and a 52 week high of $76.07.
Hologic (NASDAQ:HOLX – Get Free Report) last issued its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a return on equity of 19.58% and a net margin of 13.18%.Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.87 earnings per share. As a group, equities research analysts forecast that Hologic will post 4.28 earnings per share for the current year.
Hologic Company Profile (Get Free Report)
Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.
Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.
Recommended Stories Five stocks we like better than Hologic Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBrokerages Set Acushnet (NYSE:GOLF) Target Price at $89.57
NEXT HEADLINE »Summit Therapeutics (NASDAQ:SMMT) and Cosmos Health (NASDAQ:COSM) Financial Contrast
MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced the completion of its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, establishing Hologic as a private company. The transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) and an affiliate of GIC. In connection with the completion of this transaction, Hologic today announced the appointment of José (Joe) E. Almeida as Chief Executive Officer, effective immediately.
“Hologic is an incredible company with a storied history of innovation and an unparalleled reputation as a leader in women’s health,” said Almeida. “I am thrilled to be joining at such a pivotal moment. With the backing of Blackstone and TPG, we are poised to take the organization to new heights, with a renewed sense of purpose and greater resources to invest in innovation and initiatives that will advance the mission of enabling healthier lives around the world.”
The transaction was announced on October 21, 2025, and was approved by Hologic stockholders on February 5, 2026. With the completion of the acquisition, Hologic stockholders will receive $76 per share in cash plus a non-tradable contingent value right (CVR) to receive up to $3 per share in two payments of up to $1.50 each, for total consideration of up to $79 per share in cash. The non-tradable CVR would be paid, in whole or in part, following achievement of certain global revenue goals for Hologic’s Breast Health business in fiscal years 2026 and 2027.
Ram Jagannath, Senior Managing Director and Global Head of Healthcare at Blackstone said, “Hologic has established itself as a global leader in advancing women’s health, with a proven track record of delivering life-changing medical technologies. We are thrilled to partner with Joe Almeida — an exceptional medical technology leader — alongside Hologic’s talented team and TPG to drive the company’s next phase of growth and innovation.”
“Hologic’s mission is to advance detection and care to improve health outcomes for women worldwide,” said Alex Albert, Partner at TPG and Co-Head of Healthcare for TPG Capital. “Investing behind healthcare innovation has been a core thematic focus for TPG over decades, and we have long admired Hologic as an industry leader. Under Joe’s experienced and proven leadership, we are proud to partner with Hologic and Blackstone to support clinical excellence and deliver meaningful impact for patients.”
Almeida was most recently Chairman, President and Chief Executive Officer of Baxter International Inc., where he served from 2016 to early 2025. During his tenure, he led a strategic repositioning of the company, focusing on operational improvement, portfolio changes and medical product innovation.
Prior to Baxter, Almeida served as Chairman, President and CEO of Covidien plc until its acquisition by Medtronic in 2015. Before joining Covidien, he held senior leadership roles at Tyco Healthcare, and previously served in executive positions at Wilson Greatbatch Technologies, Acufex Microsurgical and Codman & Shurtleff, a division of Johnson & Johnson. A native of Brazil, Almeida holds a Bachelor of Science in mechanical engineering from Instituto Mauá de Tecnologia in São Paulo.
Almeida succeeds Stephen MacMillan, who recently retired from his role as Chairman, President and CEO after more than 12 years leading the organization.
Hologic’s common stock has ceased trading and will be delisted from the Nasdaq Stock Market.
About Hologic
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com.
About Blackstone
Blackstone is the world’s largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone’s $1.3 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.
About TPG
TPG is a leading global alternative asset management firm, founded in San Francisco in 1992, with $303 billion of assets under management and investment and operational teams around the world. TPG invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, and market solutions, and our unique strategy is driven by collaboration, innovation, and inclusion. Our teams combine deep product and sector experience with broad capabilities and expertise to develop differentiated insights and add value for our fund investors, portfolio companies, management teams, and communities.
This news release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “likely,” “future,” “strategy,” “potential,” “seeks,” “goal” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the benefits of closing the merger. These forward-looking statements are based upon assumptions made by Hologic as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
These forward-looking statements are subject to a number of risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, including without limitation, risks related to disruption of management time from ongoing business operations due to the transaction; the risk of any litigation relating to the transaction; the risk that the transaction could have an adverse effect on the ability of Hologic to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees and other business relationships and on its operating results and business generally; and the risk that the holders of the CVRs will receive less-than-anticipated payments with respect to the CVRs. Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements is included in the Hologic Annual Report on Form 10-K for the fiscal year ended September 27, 2025 filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2025, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings made by Hologic from time to time with the SEC. These filings, when available, are available on the investor relations section of the Hologic website at https://investors.hologic.com or on the SEC’s website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Hologic presently does not know of or that Hologic currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based, except as required by law.
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #WomensHealth--Research presented at the Society of Breast Imaging (SBI) Symposium backs Hologic AI-powered mammography technology for detecting challenging cancers.
BOSTON--(BUSINESS WIRE)--OM1 helped power a 650,000-patient real-world evidence study supporting FDA approval of Hologic's Aptima HPV Assay for cervical cancer screening.
